Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to $18.4 million.

  • Viemed Healthcare's Cash from Operations rose 4411.14% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 2962.61%. This contributed to the annual value of $39.1 million for FY2024, which is 1354.29% down from last year.
  • As of Q3 2025, Viemed Healthcare's Cash from Operations stood at $18.4 million, which was up 4411.14% from $12.3 million recorded in Q2 2025.
  • Viemed Healthcare's 5-year Cash from Operations high stood at $18.4 million for Q3 2025, and its period low was $1.2 million during Q1 2024.
  • Its 5-year average for Cash from Operations is $8.8 million, with a median of $8.0 million in 2022.
  • As far as peak fluctuations go, Viemed Healthcare's Cash from Operations soared by 66243.82% in 2021, and later tumbled by 8880.53% in 2024.
  • Over the past 5 years, Viemed Healthcare's Cash from Operations (Quarter) stood at $8.7 million in 2021, then fell by 11.22% to $7.7 million in 2022, then soared by 72.88% to $13.3 million in 2023, then increased by 12.82% to $15.0 million in 2024, then grew by 22.55% to $18.4 million in 2025.
  • Its Cash from Operations was $18.4 million in Q3 2025, compared to $12.3 million in Q2 2025 and $2.9 million in Q1 2025.